Clinical drug development is greatly affected by the inability of 2D in-vitro disease models to effectively predict physiological response towards novel drug candidates. Three dimensional (3D) cell culture systems, with higher degree of structural complexity and homeostasis akin to the in-vivo models, can potentially alleviate this problem. With this aim, the present study explores the potential application and effectiveness of biofabrication techniques in the development of two different disease models. To investigate tumor cell mechanics and tissue microenvironment in 3D, prostate cancer organoids were developed and fabricated in a biocompatible hydrogel (GelMA) for a period of 21 days. On comparative analysis, the organoids maintained their viability over long time cultures in both matrigel and GelMA, thus presenting a potential application towards 3D bioprinted co-cultured system, analogous to tissues and organs. Additionally, microfabricated lung tissue array devices were developed using photolithography and replica molding to mimic lung physiology in-vitro. These microtissues, chemically induced to mimic pulmonary fibrosis, were then used as a proof of principle to test drug efficacy for the development of a potential anti-fibrosis therapy. On testing different drug concentrations in preventative treatment regimen, the test drug was found to be effective in slowing down fibrosis in normal human lung fibroblasts (NHLF). Both of these 3D disease models, developed in-vitro, provided a much needed spatial control and partially depicted traits (cell behaviour, morphology and biomechanical characteristics) exhibited by in-vivo systems. Based on the results of the investigation, it was found that the creation of large micro-tissue constructs could potentially minimize time and costs involved with animal testing, thus accelerating translation of effective drug candidates to clinical settings.